The competitive cost of antibiotic resistance in Mycobacterium tuberculosis

被引：489

作者：

Gagneux, Sebastien ^{[1
]}

Long, Clara Davis

Small, Peter M.

Van, Tran

Schoolnik, Gary K.

Bohannan, Brendan J. M.

机构：

[1] Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA

[2] Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA

[3] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA

[4] Inst Syst Biol, Seattle, WA 98103 USA

[5] Bill & Melinda Gates Fdn, Seattle, WA 98102 USA

来源：

SCIENCE | 2006年 / 312卷 / 5782期

基金：

英国惠康基金;

关键词：

D O I：

10.1126/science.1124410

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Mathematical models predict that the future of the multidrug-resistant tuberculosis epidemic will depend on the fitness cost of drug resistance. We show that in laboratory-derived mutants of Mycobacterium tuberculosis, rifampin resistance is universally associated with a competitive fitness cost and that this cost is determined by the specific resistance mutation and strain genetic background. In contrast, we demonstrate that prolonged patient treatment can result in multidrug-resistant strains with no fitness defect and that strains with low- or no-cost resistance mutations are also the most frequent among clinical isolates.

引用

收藏

页码：1944 / 1946

页数：3

相关论文

共 28 条

[11] Will tuberculosis become resistant to all antibiotics? [J].

Dye, C ;

Espinal, MA .

PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2001, 268 (1462) :45-52

[12] Overview of resistance in the 1990s [J].

File, TM .

CHEST, 1999, 115 (03) :3S-8S

[13] Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains [J].

Fleischmann, RD ;

Alland, D ;

Eisen, JA ;

Carpenter, L ;

White, O ;

Peterson, J ;

DeBoy, R ;

Dodson, R ;

Gwinn, M ;

Haft, D ;

Hickey, E ;

Kolonay, JF ;

Nelson, WC ;

Umayam, LA ;

Ermolaeva, M ;

Salzberg, SL ;

Delcher, A ;

Utterback, T ;

Weidman, J ;

Khouri, H ;

Gill, J ;

Mikula, A ;

Bishai, W ;

Jacobs, WR ;

Venter, JC ;

Fraser, CM .

JOURNAL OF BACTERIOLOGY, 2002, 184 (19) :5479-5490

[14] Variable host-pathogen compatibility in Mycobacterium tuberculosis [J].

Gagneux, S ;

DeRiemer, K ;

Van, T ;

Kato-Maeda, M ;

de Jong, BC ;

Narayanan, S ;

Nicol, M ;

Niemann, S ;

Kremer, K ;

Gutierrez, MC ;

Hilty, M ;

Hopewell, PC ;

Small, PM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (08) :2869-2873

[15] LONG-TERM EXPERIMENTAL EVOLUTION IN ESCHERICHIA-COLI .1. ADAPTATION AND DIVERGENCE DURING 2,000 GENERATIONS [J].

LENSKI, RE ;

ROSE, MR ;

SIMPSON, SC ;

TADLER, SC .

AMERICAN NATURALIST, 1991, 138 (06) :1315-1341

[16] Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution [J].

Maisnier-Patin, S ;

Andersson, DI .

RESEARCH IN MICROBIOLOGY, 2004, 155 (05) :360-369

[17] Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis [J].

Mariam, DH ;

Mengistu, Y ;

Hoffner, SE ;

Andersson, DI .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1289-1294

[18] Programmes and principles in treatment of multidrug-resistant tuberculosis [J].

Mukherjee, JS ;

Rich, ML ;

Socci, AR ;

Joseph, JK ;

Virú, FA ;

Shin, SS ;

Furin, JJ ;

Becerra, MC ;

Barry, DJ ;

Kim, JY ;

Bayona, J ;

Farmer, P ;

Fawzi, MCS ;

Seung, KJ .

LANCET, 2004, 363 (9407) :474-481

[19] Analysis of rpoB and pncA mutations in the published literature:: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? [J].

O'Sullivan, DM ;

McHugh, TD ;

Gillespie, SH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (05) :674-679

[20] Evolution - Humans as the world's greatest evolutionary force [J].

Palumbi, SR .

SCIENCE, 2001, 293 (5536) :1786-1790